VBL Therapeutics Announces Preclinical and Clinical Data Demonstrating Substantial Tumor Reduction and Stable Disease Achieved with First-in-Class Vascular Disruptive Agent in Advanced Cancers

TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics today announced positive results from preclinical and Phase 1 studies evaluating the company’s lead anti-cancer agent, VB-111 – a first-in-class, targeted biological agent shown to work via dual-action, anti-angiogenic and vascular disruptive mechanism of action – in metastatic cancer. Preclinical data evaluating VB-111 in a comprehensive set of in vivo studies employing the Lewis Lung metastasis mouse model showed the compound to be safe and specific, with a 90% reduction in tumor burden of lung metastases after only one injection. A Phase 1 study involving 27 patients with advanced stage solid tumors demonstrated that VB-111 was well-tolerated with no dose-limiting toxicities, and promising efficacy signals. These results were presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010, taking place this week in Washington, D.C.